Talbot, A., Bobin, A., Tabone, L., Lambert, J., Boccaccio, C., Deal, C., Petillon, M.-O., Allangba, O., Agape, P., Arnautou, P., Belkhir, R., Cailleres, S., Chaoui, D., Chrétien, M.-L., Decaux, O., Schulmann, S., Frenzel, L., Gastaud, L., Huart, A., Hulin, C., Karlin, L., Laribi, K., Le Calloch, R., Lenain, P., Macro, M., Manier, S., Montes, L., Moreau, S., Moreau, P., Morel, V., Norwood, J., Piocelle, F. O., Perrot, A., Pica, G. M., Rey, P., Schmitt, A., Stoppa, A.-M., Tiab, M., Touzeau, C., Vidal, V., Vignon, M., Vincent, L., Van De Wyngaert, Z., Zarnitsky, C., Kerbouche, N., Paka, P., Leleu, X., Arnulf, B., Avet-Loiseau, H. and du Myélome, I. I. F. (2023) “Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study”, Haematologica. Pavia, Italy, 108(10), pp. 2774-2782. doi: 10.3324/haematol.2022.281772.